Drug target identification, lead identification and optimization, 3-dimensional organotypic disease models, cell-based assays, high-throughput screening, biomarker identification and validation, biomarker detection assays, peptide therapeutics and diagnostics.
Rapid identification, optimisation and pre-clinical validation of novel synthetic or biological drug candidates and the discovery of drug targets and biomarkers.
The cooperation with partners in the biotech industry, academic institutions and clinics and the international communication and interaction among a wide range of interdisciplinary research teams guarantees rapid progress in the development of novel experimental procedures and the identification of drug candidates. Collaborative ventures with industry are established either via joint grant proposals or via mission-oriented and industry-funded benchmark projects.
Selected services for industry
- Development of customised and miniaturised human cellular/organotypic disease models for the cost-effective identification and optimisation of lead candidates (including pathway-specific reporter cell analyses).
- Development of customised phenotype-based and personalised drug discovery strategies including the creation of diagnostic tools for the detection of predictive and prognostic biomarkers.
- Customised screening for peptide therapeutics or diagnostics using advanced proprietary high-throughput peptide screening platforms and complementary phage display technologies.
Relevance of the projects for the public good
The individualisation of therapies is going to change both preclinical drug discovery programmes and the clinical treatment of major human diseases. Our personalised drug discovery efforts make use of the molecular genetic information obtained from diseased cells to identify therapeutic regimens that are likely to have powerful beneficial effects in patients. Our proprietary peptide screening programmes aim at the identification of novel biological lead candidates for the treatment of cancer and inflammatory disorders. Our collaborative research efforts will be instrumental in building up regional scientific excellence and will expedite the establishment of scientific infrastructure, databases and research training facilities in Lower Austria.
The interdisciplinary and multi-institutional projects will be an incubator for future scientific efficiency and productivity, and ensure the rapid translation of scientific findings into clinical and industrial applications.